NRX Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
NRXP$2.38+4.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements Unaudited Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025
Item 1. Financial Statements
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $6,713 | $7,797 |
| Accounts receivable, net | 181 | 161 |
| Prepaid expense and other current assets | 467 | 934 |
| Total current assets | 7,361 | 8,892 |
| Investments | 399 | 397 |
| Furniture and equipment, net | 259 | 63 |
| Right-of-use assets, net | 743 | 414 |
| Right-of-use asset - related party, net | 193 | 219 |
| Intangible assets, net (provisional) | 879 | 925 |
| Goodwill (provisional) | 1,793 | 1,793 |
| Other assets | 276 | 253 |
| Total assets | $11,903 | $12,956 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $4,399 | $4,270 |
| Accrued and other current liabilities | 11,280 | 11,337 |
| Accrued clinical site costs | 340 | 351 |
| Warrant liabilities | 8,766 | 12,304 |
| Lease liability, short term | 283 | 211 |
| Lease liability, short term - related party | 108 | 105 |
| Total current liabilities | 25,176 | 28,578 |
| Lease liability, noncurrent | 455 | 199 |
| Lease liability, noncurrent - related party | 88 | 116 |
| Total liabilities | 25,719 | 28,893 |
| Commitments and Contingencies (Note 10) | ||
| Stockholders’ deficit: | ||
| Preferred stock, $0.001 par value, 50,000,000 shares authorized. | $— | $— |
| Series A convertible preferred stock, $0.001 par value, 12,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common Stock, $0.001 par value, 500,000,000 shares authorized; 33,471,315 and 31,734,333 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 33 | 32 |
| Additional paid-in capital | 294,476 | 290,926 |
| Accumulated deficit | (308,325) | (306,895) |
| Total stockholders’ deficit | (13,816) | (15,937) |
| Total liabilities and stockholders' deficit | $11,903 | $12,956 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.